High Court Upholds Pharmaceutical Companies' Amalgamation Scheme, Dismissing Objections

The High Court upheld the sanction of the scheme of amalgamation between two pharmaceutical companies, dismissing all objections raised by the Central Government, Commissioner of Income-tax, shareholder, and creditor. The court found the scheme fair, reasonable, and in the public interest, facilitating the manufacture of essential drugs and saving foreign exchange. The court determined that the amalgamation was not primarily for tax benefits but to utilize industrial licenses, ultimately rejecting appeals against the scheme and finding no substantial legal or public interest issues for Supreme Court review.

---

---

Issues Involved:
1. Approval of the Scheme of Amalgamation.
2. Objections by the Central Government.
3. Objections by the Commissioner of Income-tax.
4. Objections by a Shareholder.
5. Objections by a Creditor.
6. Date of Effectiveness of the Scheme.
7. Exchange Ratio of Shares.
8. Public Interest and Tax Implications.

Detailed Analysis:

1. Approval of the Scheme of Amalgamation:
The High Court dismissed all four appeals against the decision of the single judge who sanctioned the scheme of amalgamation between Ambalal Sarabhai Enterprises Ltd. (transferee-company) and Standard Pharmaceuticals Ltd. (transferor-company). The court found no substantial question of law of public importance to be decided by the Supreme Court and rejected the oral leave for appeal.

2. Objections by the Central Government:
The Central Government opposed the scheme on the ground that the amalgamation required prior approval under Section 23 of the Monopolies and Restrictive Trade Practices Act (MRTP Act). The court analyzed whether the scheme fell within the exceptions provided in Section 23(3) of the MRTP Act, which exempts interconnected undertakings that are not dominant and produce the same goods from requiring Central Government approval. The court concluded that both companies produced the same goods (drugs and medicines) and were not dominant undertakings, thus falling within the exception.

3. Objections by the Commissioner of Income-tax:
The Commissioner of Income-tax objected to the change in the effective date of the amalgamation from July 1, 1981, to April 1, 1980, arguing it was intended to allow the transferee-company to claim a set-off of the transferor-company's carried forward loss and unabsorbed depreciation, resulting in a tax loss of Rs. 60 lakhs. The court found that the change in the date was suggested by the shareholders of the transferor-company and was not intended to evade taxes. The court held that the amalgamation was not primarily for tax benefits but to utilize the industrial licenses held by the transferor-company.

4. Objections by a Shareholder:
A shareholder, Mr. Shodhan, contended that the exchange ratio of shares was unfair and that the scheme was not in the interest of the transferee-company. The court found that the exchange ratio was determined by chartered accountants using recognized methods and was fair. The court also dismissed the contention that the statutory requirements were not met, noting that the notice of the meeting indicated the possibility of modifications, which were duly approved.

5. Objections by a Creditor:
Albright Morarji & Pandit Ltd., a creditor of the transferee-company, opposed the scheme, arguing that a meeting of creditors should have been convened. The court found that the creditors' interests were not adversely affected by the scheme, as the transferee-company was taking over all assets and liabilities of the transferor-company. The court also noted that the creditor's claim was disputed and subject to litigation.

6. Date of Effectiveness of the Scheme:
The court addressed the change in the effective date of the amalgamation from July 1, 1981, to April 1, 1980. It found that the change was suggested to avoid considering the loss suffered by the transferor-company in determining the fair market value of its shares. The court held that the change in date was not intended to evade taxes and was reasonable.

7. Exchange Ratio of Shares:
The court examined the exchange ratio of shares and found it to be fair and reasonable. The ratio was determined by chartered accountants using recognized valuation methods. The court noted that the transferee-company would benefit from the amalgamation, including the tax set-off and the net surplus of assets.

8. Public Interest and Tax Implications:
The court considered whether the amalgamation was in public interest. It found that the amalgamation would facilitate the manufacture of essential drugs (erythromycin and ampicillin), reducing imports and saving foreign exchange. The court held that the amalgamation was in public interest and dismissed the contention that it was intended to evade taxes.

Conclusion:
The High Court upheld the sanction of the scheme of amalgamation, finding no substantial legal or public interest issues to warrant interference. The objections raised by the Central Government, Commissioner of Income-tax, shareholder, and creditor were overruled. The court found that the scheme was fair, reasonable, and in public interest.

---